Zhejiang Medicine Co., Ltd. (SHA:600216)
China · Delayed Price · Currency is CNY 11.88
-0.04 (-0.34%)
Jun 9, 2026, 3:00 PM CST
Zhejiang Medicine Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Zhejiang Medicine stock has a consensus rating of "Buy" and an average price target of ¥17.60. The average 1-year stock price forecast is 48.15% higher than the current stock price, while the lowest is ¥16.70 (+40.57%) and the highest is ¥18.50 (+55.72%).
Price Target: ¥17.60 (+48.15%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Zhejiang Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Aug '25 | Nov '25 | Dec '25 | Jan '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 2 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
9.51B
from 8.88B
Increased by 7.03%
Revenue Next Year
9.70B
from 9.51B
Increased by 2.01%
EPS This Year
1.14
EPS Next Year
n/a
from 1.14
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.5B | ||
| Avg | 9.5B | ||
| Low | 9.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 7.0% | ||
| Avg | 7.0% | ||
| Low | 7.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 1.14 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -5.8% | ||
| Low | - |